Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 11
Submit an article Journal homepage
72
Views
20
CrossRef citations to date
0
Altmetric
Drug Evaluation

Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection

Saurabh Mehandru Aaron Diamond AIDS Research Centre and the Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA. [email protected]
&
Martin Markowitz Aaron Diamond AIDS Research Centre and the Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA. [email protected]
Pages 1821-1828 | Published online: 02 Mar 2005

Bibliography

  • JONES JL, HANSON DL, DWORKIN MS et al: Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill. Summ. (1999) 48(2):1–22.
  • RICHMAN DD: HIV drug resistance. Ann. Rev Pharmacol Toxicol (1993) 33:149–164.
  • LITTLE SJ, DAAR ES, 1YAQUILA RT et al.: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 282(12):1142–1149.
  • YERLY S, VORA S, RIZZARDI P et al: Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 15(17):2287–2292.
  • BODEN D, HURLEY A, ZHANG L et al: HIV-1 drug resistance in newly infected individuals. JAMA (1999) 282(12):1135–1141.
  • LITTLE SJ, HOLTE S, ROUTY JP et al: Antiretroviral drug resistance among patients recently infected with HIV. N Engl. J. Med. (2002) 347(6):385–394.
  • •This study described the increasing incidence of drug resistance in patients with newly acquired HIV infection.
  • POPPE SM, SLADE DE, CHONG KT et al: Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother (1997) 41(5):1058–1063.
  • RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al: Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus Type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. (2000) 44(5):1328–1332.
  • •Defmed the in vitro susceptibility of multi-drug-resistant HIV to TPV.
  • LARDER BA, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14(13):1943–1948.
  • CURRY R, MARKOWITZ M, SLATER L et al.: Safety and efficacy of tipranavir, a non-peptidic protease inhibitor in multiple PI-Failure patients. Ist IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001) (Abstract 3).
  • GATHE J, KOHLBRENNER VM, PIERONE G et al: Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor patients. 10th Conference on Retro viruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 179).
  • CHONG KT, PAGANO PJ: LI vitro combination of PNU-140690, a human immunodeficiency virus Type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother (1997) 41(1 1):2367-2373. This study describes the combination of RTV with TPV.
  • DOYON L, TREMBLAY S, CARTIER M, CORDINGLEY MG: LI vitrosusceptibility of HIV-1 to tipranavir. 11th Intermational HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Seville, Spain (2002).
  • TURNER SR, STROHBACH JW, TOMMASI RA et al: Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. (1998) 41(18):3467–3476.
  • ••This is among the early and comprehensivestudies to describe the role of TPV as a PI.
  • BORIN MT, WANG Y, SCHNECK DW et al: Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retro viruses and Opportunistic Infections, Chicago, IL, USA (1998) (Abstract 648).
  • MEAL TCB, WANG Y: The safety, tolerance, pharmacokinetics and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, in a Phase I/II study. 12th World AIDS Conference, Geneva (1998) (Abstract 41176).
  • EAGLING VA, BACK DJ, BARRY MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Pharmacol (1997) 44(2):190–194.
  • MOYLE GJ, BACK D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. (2001) 2(2):105–113.
  • BALDWIN JR, BORIN MT, WANG Y, SCHNECK DW, HOPKINS NK: Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retro viruses and Opportunistic Infections, Chicago, IL, USA (1998) (Abstract 649).
  • MCCALLISTER S, SABO JP, MAYERS DL, GALITZ L: An open-label, steady-state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P450 (3A4) activity in normal, healthy volunteers. 9th Conference on RetroviCuses and Opportunistic Infections, Seattle, WA, USA (2002)
  • BALDWIN JR, BORIN MT, FERRY JJ et al.: Pharmacokinetic interaction between HIV protease inhibitors tipranavir and ritonavir 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (1999) (Abstract 657).
  • ERICKSON-VIITANEN S, MANFREDI J, VIITANEN P et al.: Cleavage of HIV-1 gag polyprotein synthesized in vitro sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses (1989) 5(6):577–591.
  • WLODAWER A, MILLER M, JASKOLSKI M et al.: Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 245(4918):616–621.
  • PENG C, HO BK, CHANG TW, CHANG NT: Role of human immunodeficiency virus Type 1-specific protease in core protein maturation and viral infectivity. J. Viral. (1989) 63(6):2550–2556.
  • HATANAKA M, NAM SH: Identification of HTLV-I gag protease and its sequential processing of the gag gene product. Cell Biochem. (1989) 40(1):15–30.
  • THAISRIVONGS S, SKULNICK HI, TURNER SR et al.: Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. I Med. Chem. (1996) 39(22):4349–4353.
  • JAPOUR AJ, MAYERS DL, JOHNSON VA et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus Type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. (1993) 37(5):1095–1101.
  • DOYON L, TREMBLAY S, WARDROP E et al: Characterization of HIV-1 showing decreased susceptibility to tipranavir and their inhibition by tipranavir-containing drug mixtures XII International HIV Drug Resistance Workshop. Los Cabos, Mexico (2003) (Abstract 14).
  • WANG Y, DAENZER CL, WOOD R et al.: The safety, efficacy and viral dynamics analysis of tipranavir, a new generation protease inhibitor, in a Phase II study in antiretroviral naive HIV-1 infected patients. 7th Conference on Retro viruses and Opportunistic Infections, San Francisco, CA, USA (2000) (Abstract 673).
  • McCALLISTER S, NEUBACHER D, VERBIEST W, MAYERS DL: Susceptibility profile of tipranavir at baseline and subsequent virologic response in a cohort of patients with multiple-PI failure. XI International HIV Drug Resistance Workshop, Seville, Spain (2002).
  • ••Phase II trial of multiple PI-experiencedpatients to determine the efficacy of TPV.
  • HALL D, McCALLISTER S, NEUBACHER D, KRAFT M, MAYERS DL: Characterization of treatment-emergent resistance mutations in two phase-II studies of tipranavir. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico (2003) (Abstract 13).
  • •Defined the emergence of treatment-related mutations in HIV from two Phase II studies of TPV.
  • JAYAWEERA DT, SLATER L, HAAS D et al.: Susceptibility profile of tipranavir at baseline and subsequent virological response in a cohort of patients with single-protease inhibitor failure. 2nd International HIV Workshop on Management of Treatment-Experienced Patients, San Diego, CA, USA (2002) (Abstract P5).
  • SLATER L, FARTHING C, JAYAWEERA J: Safety and efficacy of tipranavir (TPV), a novel non-peptidic protease inhibitor, plus ritonavir (RTV), in PI-failure patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2001) (Abstract LB–15).
  • SQUIRES K, McCALLISTER S, LAZZARIN A et al.: Tipranavir/ritonavir (TPV/r) demonstrates a uniquely robust resistance profile in multiple-protease inhibitor (PI)-experienced patients: correlation of baseline genotype and antiviral activity in BI 1182.52. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris (2003) (Abstract 812).
  • YENI P, McGREGOR T, GATHE J et al.: Correlation of viral load reduction and plasma levels in multiple protease inhibitor (PI)-experienced patients taking tipranavir/ ritonavir (TPV/r) in a Phase IIB trial. 10th Conference on Retro viruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 528).
  • ••A multi-centre, international, randomisedtrial of three doses of TPV/RTV.
  • COOPER D, HALL D, JAYAWEERA D et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir (TPV/r) is retained in isolates from patients with multiple-protease inhibitor (PI) experience. 10th Conference on Retro viruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 596).
  • MAYERS DL, KOHLBRENNER VM, DOHNANYI C et al.: The Inhibitory Quotient (IQ) of Tipranavir/Ritonavir (TPR/r) in triple class experienced HIV+ patients; results from BI 1182.52. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris (2003) (Abstract 9).
  • SABO J, MacGREGOR T, LAMSON M:Pharmacokinetics of tipranavir and nevirapine. Can. Infect. Dis. (2001) 12 (Suppl. B):40.
  • ROZKO PJ, CURRY R, BRAZINA B et al.: Standard doses of efavirenz (EFV), ziduvudine (ZDV), tenofovir (TDF) and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r). 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris (2003) (Abstract 865).
  • •Described the drug interaction of TPV with other antiretroyiral drugs.

Websites

  • http://www.unaids.org/worldaidsday/ 192002/ press/Epiupdate.html AIDS epidemic update (2002)
  • http://www.micromedex.com Thomson MICROMEDEX homepage.
  • http://www.boehringer-ingelheim.comThiv/ news/news_press_arch3.htm Tipranavir, first non-peptidic protease inhibitor, shown to suppress HIV in patients where multiple protease inhibitor-based regimes have failed (9 July, 2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.